Distribution of radioactivity and metabolite profiling in tumour and plasma following intravenous administration of a colchicine derivative ( 14C-ZD6126) to tumour-bearing mice

Xenobiotica

Volumn 37, Issue 3, 2007, Pages 328-340

  D'Souza, R A ^a   Partridge, E A ^a   Roberts, D W ^a   Ashton, S ^a   Ryan, A ^a   Patterson, A B ^b   Wilson, Z ^a   Thurrell, C C ^a  

^a ASTRAZENECA   (United Kingdom)

^b CHARLES RIVER LABORATORIES   (United Kingdom)

Author keywords

14C ZD6126; Mouse tumour xenografts; Quantitative whole body autoradiography; Tissue distribution; Vascular targeting agent

Indexed keywords

CARBON 14; COLCHICINE DERIVATIVE; N ACETYLCOLCHINOL PHOSPHATE; PHENOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HYDROLYSIS; DRUG TUMOR LEVEL; MALE; METABOLITE; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; RADIOACTIVITY; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; TUMOR NECROSIS; TUMOR XENOGRAFT; WHOLE BODY AUTORADIOGRAPHY;

ANIMALS; AUTORADIOGRAPHY; CARBON RADIOISOTOPES; COLCHICINE; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; ORGANOPHOSPHORUS COMPOUNDS; TUBULIN MODULATORS;

MUS;

EID: 33947329661     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250601169824     Document Type: Article

References (16)

1. Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ. 2002a. Antitumour activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clinical Cancer Research 8:1974-1983.
2. Blakey DC, Ashton SE, Westwood FR, Walker M, Ryan AJ. 2002b. ZD6126: A novel small molecule vascular targeting agent. International Journal of Radiation, Oncology, Biology, Physics 54(5):1497-1502.
3. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MRL, Chaplin DJ, Hill SA. 2002. ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Research 62:7247-7253.
4. Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, Langmuir P, Wheeler C, Stone A, Leadbetter J, Ryan AJ, Blakey DC, Waterton JC. 2004. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clinical Cancer Research 10:3650-3657.
5. Goertz DE, Yu JL, Kerbel RS, Burns PN, Foster FS. 2002. High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Research 62:6371-6375.
6. Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC, Sone S. 2002. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. Cancer Research 62:3711-3715.
7. Horsman MR, Murata R. 2003. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. International Journal of Radiation, Oncology, Biology, Physics 57(4):1047-1055.
8. Judson I, Scurr M, Roberts DW, Partridge EA, D'Souza RA, Tan S. 2007. Pharmacokinetics and metabolism of ZD6126 in patients with solid tumours (in preparation).
9. Lenz EM, D'Souza RA, Jordan A, King CD, Smith S, Phillips P, McCormick A, Roberts DW. 2007. HPLC-NMR with severe column overloading: Fast track metabolite identification in urine and bile samples from rat and dog treated with [14C]-ZD6126. Journal of Pharmaceutical and Biomedical Analysis (in press).
10. McCarty MF, Takeda A, Stoeltzing O, Liu W, Fan F, Reinmuth N, Akagi M, Bucana C, Mansfield PF, Ryan A, Ellis LM. 2004. ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer. British Journal of Cancer 90:705-711.
11. 14C]-ZD6126 in rat and dog (in preparation).
12. 14C]-ZD6126 in patients with solid malignant tumors [abstract]. Journal of Clinical Oncology 22(14S):3083.
13. Siemann DW, Rojiani AM. 2002. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. International Journal of Radiation, Oncology, Biology, Physics 53(1):164-171.
14. Siemann DW, Chaplin DJ, Horsman MR. 2004. Vascular-targeting therapies for treatment of malignant disease. Cancer 100(12):2491-2499.
15. Soltau J, Drevs J. 2004. ZD-6126 AstraZeneca. IDrugs 7(4):380-387.
16. Varghese HJ, MacKenzie LT, Groom AC, Ellis CG, Ryan A, MacDonald IC, Chambers AF. 2004. In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model. Angiogenesis 7:157-164.